《极高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》 - Suppr

Suppr

超能文献

[Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients].

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):280-286. doi: 10.3760/cma.j.cn112148-20200121-00036.

DOI:10.3760/cma.j.cn112148-20200121-00036

PMID:32370478

Abstract

摘要

相似文献

[Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients].《极高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》

Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):280-286. doi: 10.3760/cma.j.cn112148-20200121-00036.

[Chinese expert consensus on non-traditional blood lipid parameters to control the risks of arteriosclerotic cardiovascular disease].《中国非传统血脂参数防治动脉粥样硬化性心血管疾病风险专家共识》

Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Apr 6;56(4):405-421. doi: 10.3760/cma.j.cn112150-20211130-01106.

[China expert consensus on the management of dyslipidemia in postmenopausal patients with early-stage breast cancer].《中国绝经后早期乳腺癌患者血脂异常管理专家共识》

Zhonghua Zhong Liu Za Zhi. 2017 Jan 23;39(1):72-77. doi: 10.3760/cma.j.issn.0253-3766.2017.01.014.

Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Ann Pharmacother. 2018 Jan;52(1):91. doi: 10.1177/1060028017732358. Epub 2017 Sep 12.

Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention.美国心脏病学会与国家脂质协会就使用非他汀类疗法预防动脉粥样硬化性心血管疾病达成的共识。

J Clin Lipidol. 2016 May-Jun;10(3):458-61. doi: 10.1016/j.jacl.2016.04.004. Epub 2016 Apr 19.

Author's Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Ann Pharmacother. 2018 Jan;52(1):92-93. doi: 10.1177/1060028017732359. Epub 2017 Sep 18.

[Consensus standpoints from expert panel of Chinese Society of Cardiology on AHA/ACC 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults].

Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Apr;42(4):275-6.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.2016年美国心脏病学会临床专家共识文件特别工作组报告：非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用专家共识决策路径

J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1.

[Chinese expert consensus on blood lipid related cardiovascular residual risk control].

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jul;40(7):547-53.

Longitudinal association of egg consumption habits with blood lipids among Chinese adults: results from the Prediction for Atherosclerotic Cardiovascular Disease Risk in China project.中国成年人鸡蛋消费习惯与血脂的纵向关联：中国动脉粥样硬化性心血管疾病风险预测项目的结果

Chin Med J (Engl). 2022 Mar 20;135(6):747-749. doi: 10.1097/CM9.0000000000001555.

引用本文的文献

Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea: Implications for East Asians?中国、日本和韩国的动脉粥样硬化性心血管疾病风险预测模型：对东亚人有何启示？

JACC Asia. 2025 Mar;5(3 Pt 1):333-349. doi: 10.1016/j.jacasi.2025.01.006.

Assessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial.评估阿利西尤单抗对极高风险动脉粥样硬化性心血管疾病患者薄帽纤维粥样斑块和内皮功能的影响：一项随机对照试验的研究方案

Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1236-1246. doi: 10.21037/cdt-24-336. Epub 2024 Dec 19.

Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis.急性冠脉综合征患者强化降脂治疗的获益：系统评价和荟萃分析。

Ann Med. 2024 Dec;56(1):2389470. doi: 10.1080/07853890.2024.2389470. Epub 2024 Aug 10.

LDL-C rebound after long-term evolocumab treatment and intravascular imaging evidence in a familial hypercholesterolemia patient with early-onset myocardial infarction.长期依洛尤单抗治疗后低密度脂蛋白胆固醇反弹及血管内成像证据：一名早发心肌梗死的家族性高胆固醇血症患者的病例分析

Chronic Dis Transl Med. 2023 Oct 5;10(1):69-74. doi: 10.1002/cdt3.97. eCollection 2024 Mar.

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.中国急性心肌梗死患者使用依洛尤单抗降低低密度脂蛋白胆固醇（LDL-C）的成本效益分析方法及结果

Cost Eff Resour Alloc. 2023 Dec 1;21(1):93. doi: 10.1186/s12962-023-00501-4.

2023 China Guidelines for Lipid Management.《2023年中国血脂管理指南》

J Geriatr Cardiol. 2023 Sep 28;20(9):621-663. doi: 10.26599/1671-5411.2023.09.008.

2023 Chinese guideline for lipid management.《2023年中国血脂管理指南》

Front Pharmacol. 2023 Aug 29;14:1190934. doi: 10.3389/fphar.2023.1190934. eCollection 2023.

Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis.院内使用依洛尤单抗治疗对急性心肌梗死患者脂蛋白(a)的影响：一项回顾性队列研究和倾向评分匹配分析

Cardiol Plus. 2023 Jan-Mar;8(1):46-52. doi: 10.1097/CP9.0000000000000036. Epub 2023 Apr 27.

Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial.血脂康对比普伐他汀对 2 型糖尿病合并血脂异常患者甘油三酯水平的影响：一项多中心随机对照试验研究方案。

Curr Vasc Pharmacol. 2023;21(3):211-217. doi: 10.2174/1570161121666230328110215.

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.急性心肌梗死后院内起始 PCSK9 抑制剂治疗和短期血脂控制。

Lipids Health Dis. 2022 Oct 24;21(1):105. doi: 10.1186/s12944-022-01724-9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验